PTC Therapeutics Officer Neil Almstead Reported Selling $8.85M in Stock
PTCT has more than doubled off its 52-week low of $35.95 on light trading volume (0.1× avg).
Summary
A Form 144 filing by the spouse of PTC Therapeutics officer Neil G. Almstead disclosed that the officer recently sold approximately $8.85 million worth of common stock.
Key Events · Ownership and Investor Activity · PTCT
-
Officer Stock Sale Reported
Neil G. Almstead, an officer at PTC Therapeutics, sold 107,500 shares of common stock for gross proceeds of approximately $8.85 million in November 2025.
-
Spouse's Proposed Minor Sale
Zheng Y. Almstead, spouse of the officer, filed a Form 144 indicating intent to sell 54 shares valued at approximately $4,155, primarily to cover tax obligations from a vested equity award.
Analysis · PTCT · Life Sciences
This Form 144 filing, submitted by the spouse of PTC Therapeutics officer Neil G. Almstead, reveals significant insider selling activity. While the immediate filing indicates an intent to sell a small number of shares by the spouse for tax purposes, it also reports that officer Neil G. Almstead sold 107,500 shares totaling approximately $8.85 million in November 2025. Such a substantial sale by a company officer is a notable event for investors, as it can be interpreted as a move to realize gains or a change in personal investment strategy, and is often closely watched for potential signals regarding the officer's outlook on the company's future.
How filings like this one have moved
In the 30 days to Sep 14, 2026, 29.9% of the 1591 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was -0.24%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, PTCT was trading at $78.44 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $6.3B. The 52-week trading range was $35.95 to $87.50. This filing was assessed with negative market sentiment and an importance score of 7 out of 10.